A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

Start Date06 Sep 2023

Sponsor / Collaborator

Artios Pharma Ltd.

NCT04657068

/ RecruitingPhase 1/2

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to:
* Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan
* Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan
* Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Start Date27 Jan 2021

Sponsor / Collaborator

Artios Pharma Ltd.

100 Clinical Results associated with Alnodesertib

100 Translational Medicine associated with Alnodesertib

100 Patents (Medical) associated with Alnodesertib

Literatures (Medical) associated with Alnodesertib

07 May 2025·Journal of the American Chemical Society

Ruthenium-Catalyzed Enantioselective Alkylation of Sulfenamides: A General Approach for the Synthesis of Drug Relevant S-Methyl and S-Cyclopropyl Sulfoximines

Article

Author: Boyer, Zachary W. ; Ellman, Jonathan A. ; Kwon, Na Yeon

Sulfoximines are increasingly utilized in pharmaceuticals and agrochemicals with all sulfoximine clinical candidates incorporating either an S-methyl or an S-cyclopropyl substituent. Here, we report on a general and efficient sequence for the asymmetric synthesis of both of these sulfoximine substitution patterns. The asymmetric synthesis of sulfilimine intermediates by the first Ru-catalyzed enantioselective alkylation of sulfenamides enables the first examples of enantioselective S-alkylation with monosubstituted diazo compounds. The reaction proceeds at ≤1 mol % Ru-catalyst loading, and for tert-butyl diazoacetate, high yields and ≥98:2 er are achieved for an exceedingly broad range of sulfenamides, including with S-(hetero)aryl, -alkenyl, -methyl, -benzyl, -branched alkyl, and -tert-butyl substituents and for sterically and electronically diverse N-acyl groups. Sulfenamides derived from densely functionalized advanced drug intermediates also alkylated with 99:1 er. After oxidation of an N-pivaloyl S-tert-butyl acetate substituted sulfilimine to the corresponding sulfoximine, treatment with trifluoracetic acid in an aprotic solvent resulted in decarboxylation to the S-methyl N-pivaloyl sulfoximine, while aqueous HCl resulted in both decarboxylation and cleavage of the N-acyl group to give the S-methyl NH sulfoximine. Alternatively, sulfoximine alkylation with dibromoethane followed by acid-mediated decarboxylation provided the S-cyclopropyl sulfoximine. The efficient asymmetric synthesis of the preclinical candidate LTGO-33 and the formal asymmetric synthesis of the phase II clinical candidate ART0380 demonstrate the utility of the disclosed approach.

15 May 2024·CLINICAL CANCER RESEARCH

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Article

Author: Di Francesco, M. Emilia ; Holla, Vijaykumar ; Lazar, Alexander J. ; Smith, Graeme C.M. ; Shaw, Kenna Rael ; Sanchez, Nora S. ; Lillo, Giorgia ; Yap, Timothy A. ; Marszalek, Joseph R. ; Liu, Chiu-Yi ; Tse, Wai Yiu ; Carroll, Christopher L. ; Gheeya, Jinesh S. ; Giuliani, Virginia ; Le, Hung ; Machado, Annette A. ; Kyewalabye, Keith ; Piscitello, Desiree ; McGrail, Daniel J. ; Elinati, Elias ; Geck Do, Mary K. ; Wani, Khalida M. ; Vellano, Christopher P. ; Grinkevich, Vera ; Yang, Dong ; Feng, Ningping ; Geo, Lerin ; Kopetz, Scott E. ; Johnson, Michael G. ; Goswamy, Rohit Vivek ; Johnson, Timothy I. ; Majithiya, Jayesh ; Armstrong, Lucy ; Pilié, Patrick G. ; Ranzani, Marco ; Neves, Joana ; Heffernan, Timothy P. ; Jones, Philip ; Robinson, Helen M.R. ; Wang, Wei-Lien ; Rajendra, Eeson ; Lively, Sarah ; Bristow, Christopher A. ; Campbell, Erick ; Bardenhagen, Jennifer P. ; Ma, XiaoYan ; Luzarraga, Marina Roy ; Boursier, Marie ; Ngoi, Natalie Y.L. ; Likhatcheva, Maria ; Meric-Bernstam, Funda

Abstract:

Purpose::

Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed.

Experimental Design::

We present the first disclosure and preclinical development of a novel, selective ATR inhibitor, ART0380, and test its antitumor activity in multiple preclinical cancer models. To refine ATM LOF as a predictive biomarker, we performed a comprehensive pan-cancer analysis of ATM variants in patient tumors and then assessed the ATM variant-to-protein relationship. Finally, we assessed a novel ATM LOF biomarker approach in retrospective clinical data sets of patients treated with platinum-based chemotherapy or ATR inhibition.

Results::

ART0380 had potent, selective antitumor activity in a range of preclinical cancer models with differing degrees of ATM LOF. Pan-cancer analysis identified 10,609 ATM variants in 8,587 patient tumors. Cancer lineage–specific differences were seen in the prevalence of deleterious (Tier 1) versus unknown/benign (Tier 2) variants, selective pressure for loss of heterozygosity, and concordance between a deleterious variant and ATM loss of protein (LOP). A novel ATM LOF biomarker approach that accounts for variant classification, relationship to ATM LOP, and tissue-specific penetrance significantly enriched for patients who benefited from platinum-based chemotherapy or ATR inhibition.

Conclusions::

These data help to better define ATM LOF across tumor types in order to optimize patient selection and improve molecularly targeted therapeutic approaches for patients with ATM LOF cancers.

H3K27M-driven hypertranscription leads to a new targetable dependency in diffuse midline gliomas

Article

Author: Bartyńska, Magdalena ; Nazaretian, Ashot ; Stiles, Charles ; Mirza, Tasmia ; Smith, Graeme ; Wang, Heng ; Michor, Franziska ; Mueller, Sabine ; Wójcikowska, Olga ; Robinson, Helen ; Agar, Nathalie Y.R. ; Kohli, Khushi ; Geisberg, Jacob ; Knowles, Truman ; Pal, Sharmistha ; Graser, Christopher J. ; Boulton, Simon J. ; Bootz, Kaitlyn ; Majithiya, Jayesh B. ; Haas-Kogan, Daphne ; Chowdhury, Dipanjan

Abstract:

Diffuse midline gliomas (DMGs) are driven by the H3K27M oncohistone—a challenging therapeutic target. However, conventional therapeutic modalities are never curative. Against this backdrop, we address an important unresolved question--are there H3K27M-induced oncogenic vulnerabilities that can be exploited for therapeutic benefit. We show that H3K27M induces hypertranscription, thus identifying hypertranscription as a new molecular feature of H3K27M-driven DMGs. We demonstrate this finding in genetic mouse models, human DMG cells, and primary tumor specimens. We further demonstrate that H3K27M-induced hypertranscription perturbs replication, heightens basal replication stress, and enhances sensitivity to ATR inhibition. In exploring therapeutic implications of these findings, we document brain penetrance, target engagement, and therapeutic efficacy of a clinical-stage ATR inhibitor (alnodesertib) in vitro and in intracranial DMG xenografts. We further demonstrate synergistic activity of alnodesertib with radiotherapy—the current standard of care for DMGs. These findings provide the mechanistic underpinning and preclinical rationale for including alnodesertib as monotherapy and in combination with radiation in clinical trials for children with H3K27M DMGs. The broad implications of our studies highlight ATR inhibition as a therapy for aggressive human cancers displaying hypertranscription.

News (Medical) associated with Alnodesertib

26 May 2026

·www.biospace.com

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is supported by U.S. FDA Fast Track designation CAMBRIDGE, United Kingdom and NEW YORK, May 26, 2026 – Artios Pharma Limited (“Artios” or “the Company”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced the dosing of the first patient in a randomized Phase 2 clinical trial ( NCT05898399 ). The global study is evaluating Artios’ potential first-in-class DNA Polymerase Theta (Polθ) inhibitor, ART6043, in combination with the PARP inhibitor olaparib, in adult patients with germline BRCA-mutated (gBRCAm) HER2-negative breast cancer who are eligible to receive a PARP inhibitor. The Phase 2 POLKA trial is supported by Phase 1/2a clinical data for ART6043, which show an attractive tolerability profile, expected PK/PD activity, and promising clinical signals. The POLKA trial is designed to investigate the safety and tolerability of ART6043 plus olaparib and to evaluate the preliminary efficacy of the combination compared to olaparib alone. Artios was granted a Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2026 for the combination treatment regimen in this patient population. The supporting Phase 1/2a data were presented at the 2025 European Society of Medical Oncology (ESMO) Congress. “Dosing the first patient in the Phase 2 POLKA study marks a significant step in realizing the potential of ART6043 and advancing a new class of targeted therapies for patients with gBRCAm HER2-negative breast cancer,” said Ian Smith, Chief Medical Officer of Artios . “Patients continue to face limited effective treatment options, underscoring the need for new therapies beyond current standards of care. With Fast Track designation and this study now underway, we are focused on establishing ART6043 as a potential first‑in‑class therapy that can deliver more meaningful benefits for patients.” “While PARP inhibitors have become a cornerstone of treatment for HER2-negative breast cancer, there remains a significant need for more effective combination strategies to overcome resistance,” added Graeme Smith, Chief Scientific Officer of Artios . “By targeting the complementary DNA repair pathway mediated by Polθ, ART6043 is rationally designed to enhance the cancer cell killing activity of PARP inhibition and to potentially prevent the emergence of resistance to PARP inhibition. We look forward to evaluating this in the Phase 2 POLKA study.” The global, multicentre, Phase 2 trial is enrolling 80 patients randomized 1:1 with gBRCAm HER2-negative, locally advanced or metastatic breast cancer who received up to three prior lines of chemotherapy and no or ≤ 1 month of prior treatment with a PARP inhibitor. Eligible patients will be assigned to receive ART6043 plus olaparib or olaparib alone to assess comparative efficacy as measured by the primary endpoint, progression-free survival. Secondary endpoints include overall response rate, overall survival, and a comparison of the rate of BRCA mutation reversion. About ART6043 ART6043 is a potential first-in-class, selective, orally bioavailable, small‑molecule inhibitor of the polymerase domain of DNA polymerase theta (Polθ), a DNA repair enzyme that is preferentially expressed in cancer cells but is virtually absent in most healthy tissues. By inhibiting Polθ, ART6043 targets microhomology-mediated end joining (MMEJ) to exploit tumor dependence on error-prone DNA repair, with broad rationale for use as a combination partner with PARP inhibition and other DNA‑damaging modalities. Artios’ differentiated approach is to evaluate ART6043 with olaparib in molecularly defined solid tumors such as gBRCAm cancers. The Phase1/2a study of ART6043 highlighted an attractive tolerability pro combination with the leading PARP inhibitor olaparib, expected PK/PD activity, and promising clinical signals. About Artios Pharma Ltd. Artios’ mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells’ survival mechanisms, driving cancer cell death and improving clinical outcomes. Visit our website at to learn more about Artios. For more information, please contact: Trophic Communications Jacob Verghese or Verena Schossmann Tel: +49 151 219 412 77 Email: artios@trophic.eu

Phase 2Fast Track

12 May 2026

·www.biospace.com

Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors

CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced a clinical trial collaboration and supply agreement with GSK to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez), GSK’s novel investigational B7-H3-targeting topoisomerase-1 (Topo-1) antibody-drug conjugate (ADC), in patients with gastrointestinal tumors. “We’re excited to collaborate with GSK to investigate the potential of this combination strategy to provide meaningful benefit to patients with GI tumors,” said Mike Andriole, Chief Executive Officer of Artios . “As we advance the development of alnodesertib in multiple solid tumors, this collaboration enables Artios to broaden our combinatorial strategy and unlock the full potential of exploiting replication stress biology in cancer.” Under the terms of the agreement, GSK will sponsor and conduct the Phase 1 study and provide its B7-H3 Topo-1 ADC, while Artios will supply alnodesertib. Each party will maintain rights to its respective products, and the agreement is mutually non-exclusive. The clinical study is expected to open by the end of the year. About risvutatug rezetecan Ris-Rez is a novel investigational B7-H3-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez. GSK’s global phase III trial (NCT07099898) for Ris-Rez in relapsed extensive stage small-cell lung cancer (ES-SCLC) began in August 2025. Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labor and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC; and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA. About alnodesertib Alnodesertib, formerly known as ART0380, is a potential first-in-class, orally administered, selective small molecule inhibitor of ataxia-telangiectasia and Rad3-related protein (ATR). Artios is developing alnodesertib in patients whose tumor harbours high degrees of replication stress using ATM status as a key biomarker. When used in combination with low-dose chemotherapy to further amplify replication stress, alnodesertib demonstrated unprecedented response rates across eight different solid tumors in ATM-deficient patients. Alnodesertib has received U.S. Fast Track designation in combination with a low dose of chemotherapeutic agent irinotecan, for the treatment of adult patients with ATM-negative metastatic colorectal cancer (mCRC) in the third-line setting. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at About Artios Pharma Ltd. Artios’ mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells’ survival mechanisms, driving cancer cell death and improving clinical outcomes. Visit our website at to learn more about Artios. For more information, please contact: Trophic Communications Jacob Verghese or Verena Schossmann Tel: +49 151 7441 6179 Email: artios@trophic.eu Attachment PDF Version

04 May 2026

·www.biospace.com

Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution

Jeremy B. Fitch, MBA, appointed as Chief Business Officer Michael A. Alrutz, J.D., Ph.D., appointed as General Counsel Guy C. Ruble, PharmD, appointed as VP, Regulatory Affairs CAMBRIDGE, United Kingdom and NEW YORK, May 04, 2026 – Artios Pharma Limited (“Artios” or “the Company”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced the appointment of three senior executives to the leadership team as the Company accelerates its potential first-in-class oncology pipeline. Jeremy B. Fitch, MBA, joins as Chief Business Officer (CBO) and will shape Artios’ corporate business development and strategic partnerships. Michael A. Alrutz, J.D., Ph.D., joins as General Counsel and will oversee Artios’ legal, corporate governance, regulatory compliance, risk management, and intellectual property management, while serving as a strategic partner to the Board of Directors and executive leadership team. Guy C. Ruble, PharmD, has been appointed as Vice President of Regulatory Affairs to lead the Company’s regulatory strategy and initiatives. These appointments come as Artios advances alnodesertib into late-stage development and prepares for potential U.S. commercialization, executes a randomized Phase 2 study for ART6043, and rapidly advances its DNA Damage Response antibody drug conjugate platform toward clinical development. “Jeremy brings a proven track record of executing high‑impact transactions and shaping portfolio and corporate strategy,” said Mike Andriole, Chief Executive Officer of Artios. “His appointment as CBO, together with Michael’s deep legal and governance expertise and Guy’s leadership in global regulatory strategy, comes at a pivotal inflection point as we progress alnodesertib toward potential registration and commercialization. These leadership additions further strengthen our ability to execute with discipline, accelerate paths to registration, and urgently deliver first‑in‑class therapies to patients with late‑stage cancers who need more treatment options.” “With three potentially first-in-class DDR programs under rapid development, Artios is uniquely positioned with a differentiated pipeline and clear opportunities to create long-term value,” said Jeremy B. Fitch, MBA, Chief Business Officer of Artios. “I look forward to working with the rest of the management team to develop and execute value-creating transactions which leverage our substantial DDR scientific and clinical expertise.” Jeremy B. Fitch, MBA, Chief Business Officer Jeremy joins Artios with more than 30 years of experience in the biopharmaceutical industry with Eli Lilly and Company (“Lilly”), across operational, financial, and corporate business development roles. Jeremy spent the past 15 years in Lilly’s Corporate Business Development group, most recently as Vice President of Transactions, where he led strategic deal-making spanning M&A, asset acquisitions/divestitures, and licensing agreements. Having led more than $5 billion in transactions during his career, Jeremy has been central to developing and implementing strategies that have driven substantial value creation across Lilly’s pipeline. Jeremy is a Certified Licensing Professional and holds an MBA from Duke University’s Fuqua School of Business. Michael A. Alrutz, J.D., Ph.D., General Counsel Dr. Alrutz is a seasoned General Counsel and Corporate Secretary, bringing 25 years of biotechnology legal affairs experience to Artios across both private and public biopharmaceutical companies. Dr. Alrutz brings a strong track record advising leadership teams through complex corporate inflection points, including IPOs, follow-on financings, intellectual property matters, pre-commercialization matters, and high-value corporate transactions. Most recently, he was SVP, General Counsel, Secretary, and Chief Compliance Officer at Chimerix, where he led SEC compliance, board governance, intellectual property management, and the legal facets of corporate transactions, including the company’s $935 million all-cash merger with Jazz Pharmaceuticals as the company prepared for commercialization of Modeyso® (dordaviprone). Previously, while General Counsel at Trimeris, Inc., he provided legal counsel for the company’s commercial launch of its antiretroviral, Fuzeon® (enfuvirtide). Dr. Alrutz is registered to practice before the USPTO, and holds a J.D. from Duke University School of Law, and a Ph.D. in Microbiology and Molecular Biology from Tufts University. Guy C. Ruble, PharmD, VP of Regulatory Affairs Guy brings more than 20 years of regulatory affairs leadership and nearly three decades of biopharmaceutical industry experience to Artios. He most recently served as Vice President of Regulatory Affairs at Iovance Biotherapeutics, where he led the U.S. FDA accelerated approval of AMTAGVI® (li ), the first tumor-infiltrating lymphocyte (TIL) therapy approved in the United States and Canada, and also led global submissions across Europe and Asia. Prior to Iovance, Guy spent nearly 23 years at Eli Lilly and Company, leading global regulatory strategy for multiple oncology programs, including the U.S. FDA approval of Verzenio® (abemaciclib). He earned recognition as a Top 100 Lilly Innovator. Guy holds a Doctor of Pharmacy (PharmD) from Purdue University and is Regulatory Affairs Certified (RAC-US). He is a member of the Regulatory Affairs Professional Society and the American Society of Clinical Oncology. About Artios Pharma Ltd. Artios’ mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells’ survival mechanisms, driving cancer cell death and improving clinical outcomes. Visit our website at to learn more about Artios. For more information, please contact: Trophic Communications Jacob Verghese or Verena Schossmann Tel: +49 151 7441 6179 Email: artios@trophic.eu Attachment Artios Leadership PR

Drug ApprovalPhase 2Executive Change

100 Deals associated with Alnodesertib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Solid Tumor	Phase 2	United States	Artios Pharma Ltd.	06 Sep 2023
Metastatic Solid Tumor	Phase 2	France	Artios Pharma Ltd.	06 Sep 2023
Metastatic Solid Tumor	Phase 2	Spain	Artios Pharma Ltd.	06 Sep 2023
Acinar Cell Carcinoma	Phase 2	United States	Artios Pharma Ltd.	27 Jan 2021
Acinar Cell Carcinoma	Phase 2	France	Artios Pharma Ltd.	27 Jan 2021
Acinar Cell Carcinoma	Phase 2	Spain	Artios Pharma Ltd.	27 Jan 2021
Acinar Cell Carcinoma	Phase 2	United Kingdom	Artios Pharma Ltd.	27 Jan 2021
Advanced cancer	Phase 2	United States	Artios Pharma Ltd.	27 Jan 2021
Advanced cancer	Phase 2	France	Artios Pharma Ltd.	27 Jan 2021
Advanced cancer	Phase 2	Spain	Artios Pharma Ltd.	27 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04657068 (STELLA, ASCO2026)	Phase 1	Pancreatic Ductal Adenocarcinoma ATM-negative	100	Alnodesertib 200mg + Irinotecan 60mg/m2	glkdlkejew(dwvlbfqteq) = nywugafvje axupysdoov (ttbejjulga ) View more	Positive	29 May 2026
NCT04657068 (GEICO 114-O, ESGO2026)	Phase 2	Platinum-Resistant Ovarian Carcinoma	64	Alnodesertib + Gemcitabine	rimingqlqc(zpkqkgouwp): HR = 0.71 (90.0% CI, 0.46 - 1.1), P-Value = 0.09 View more	Positive	28 Feb 2026
				Gemcitabine
NCT04657068 (AACR2025) Manual	Phase 1/2	Solid tumor	87	ART0380 + irinotecan	ztogwcuipn(fcinubqssv) = The most common treatment related adverse events were neutropenia (53%), anemia (41%), fatigue (33%) and diarrhea (31%). Grade≥3 related diarrhea, nausea and vomiting each occurred in 1 pt. gywpnotoyp (ckmiaiqvjl )	Positive	29 Apr 2025
				ART0380 + irinotecan (ATM negative)
NCT04657068 (ESMO2023) Manual	Phase 1	Advanced Malignant Solid Neoplasm	49	ART0380 intermittent doses between 100mg and 1200mg	xnkzontsgf(trnqfzqgtm) = 36% of pts experienced the only Grade 3 treatment-related adverse event of anemia svvueickuo (vuqeaidtxx ) View more	Positive	23 Oct 2023
				ART0380 QD doses of 200mg and 400mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis